Posted on 06/02/2009 in Medical Company Financials Haemonetics has revealed its year to date net revenues have risen 18 per cent.
Now standing at $445 million (303 million pounds), the figure was joined by a 35 per cent growth in operating income to $67 million over the same period.
The company also announced in its third-quarter fiscal 2009 results that net earnings per share were up 15 per cent to $0.62.
Commenting on the figures, Haemonetics' chairman and chief executive officer Brad Nutter said the company was "seeing strength" in its diversified product lines, despite the current economic climate.
He added: "I'm particularly pleased to note that year-to-date reported revenue growth is double digits in all of our geographies."
Mr Nutter went on to note the company's outlook for the future was "strong".
In October last year, the organisation announced its generally accepted accounting principle net revenues were up 20 per cent to $146 million, while its operating income increased 62 per cent to $24 million.Other news stories from 06/02/2009
Read more in the Zenopa News Archive
How this news is generated
|
